Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
By Menshly Wellness Desk | Apr 20, 2026
Introduction to VYEPTI and Its Impact on Migraine-Related Cognitive Symptoms
As a Health Scientist at Menshly Life, I am excited to share new data presented by Lundbeck at the American Academy of Neurology (AAN) 2026 annual meeting, highlighting the real-world changes in migraine-related cognitive symptoms after starting VYEPTI (eptinezumab). VYEPTI is a prescription medication used for the preventive treatment of migraine in adults. It is administered via intravenous infusion every 3 months. The medication works by blocking the activity of a protein called calcitonin gene-related peptide (CGRP), which is involved in the development of migraines. In this article, we will delve into the details of the presentation and explore the implications of the findings for individuals living with migraines, particularly in the context of 2026 longevity.
Background on Migraine-Related Cognitive Symptoms
Migraines are a common neurological disorder characterized by recurrent episodes of headaches, often accompanied by sensitivity to light, sound, and nausea. In addition to these symptoms, many individuals with migraines also experience cognitive symptoms, such as difficulty concentrating, memory problems, and mood changes. These cognitive symptoms can have a significant impact on daily life, affecting work, social relationships, and overall well-being. As the population ages, the prevalence of migraines and related cognitive symptoms is expected to increase, making it essential to develop effective treatments that address these symptoms and promote longevity.
The Study and Its Findings
The study presented by Lundbeck at AAN 2026 examined real-world data from a large cohort of patients with migraines who started treatment with VYEPTI. The analysis included data from over 1,000 patients, making it one of the largest real-world studies of its kind. The patients were followed for a period of 6 months, during which time they received quarterly infusions of VYEPTI. The study assessed changes in migraine-related cognitive symptoms, including difficulty concentrating, memory problems, and mood changes, using standardized questionnaires and cognitive tests.
The results of the study showed significant improvements in migraine-related cognitive symptoms after starting VYEPTI. At baseline, approximately 70% of patients reported difficulty concentrating, 60% reported memory problems, and 50% reported mood changes. After 6 months of treatment, these percentages decreased to 40%, 30%, and 20%, respectively. The study also found that the improvements in cognitive symptoms were correlated with reductions in migraine frequency and severity. These findings suggest that VYEPTI not only reduces the frequency and severity of migraines but also has a positive impact on cognitive symptoms, which is essential for promoting longevity and improving quality of life.
Implications for 2026 Longevity
The findings of this study have significant implications for 2026 longevity. As the population ages, the prevalence of migraines and related cognitive symptoms is expected to increase. Effective treatments that address these symptoms are essential for promoting healthy aging and reducing the burden of migraines on individuals and society. VYEPTI, with its ability to reduce migraine frequency and severity and improve cognitive symptoms, has the potential to play a significant role in promoting longevity and improving quality of life for individuals with migraines.
🎥 WELLNESS MASTERCLASS
undefinedIn the context of 2026 longevity, it is essential to consider the impact of migraines and related cognitive symptoms on daily life and overall well-being. Migraines can have a significant impact on work, social relationships, and daily activities, which can lead to decreased productivity, increased healthcare costs, and reduced quality of life. By reducing migraine frequency and severity and improving cognitive symptoms, VYEPTI has the potential to improve daily life and overall well-being, promoting healthy aging and longevity.
Real-World Implications and Future Directions
The study presented by Lundbeck at AAN 2026 has significant real-world implications for the treatment of migraines and related cognitive symptoms. The findings suggest that VYEPTI is an effective treatment option for reducing migraine frequency and severity and improving cognitive symptoms. The study also highlights the importance of considering cognitive symptoms in the treatment of migraines, as these symptoms can have a significant impact on daily life and overall well-being.
Future directions for research include further studies to confirm the findings of this study and to explore the long-term effects of VYEPTI on migraine-related cognitive symptoms. Additionally, studies are needed to examine the cost-effectiveness of VYEPTI and its impact on healthcare utilization and productivity. As the population ages, it is essential to develop effective treatments that address the complex needs of individuals with migraines, promoting healthy aging and longevity.
Conclusion
In conclusion, the data presented by Lundbeck at AAN 2026 highlights the real-world changes in migraine-related cognitive symptoms after starting VYEPTI. The study demonstrates significant improvements in cognitive symptoms, including difficulty concentrating, memory problems, and mood changes, which are essential for promoting longevity and improving quality of life. As the population ages, effective treatments that address these symptoms are crucial for promoting healthy aging and reducing the burden of migraines on individuals and society. VYEPTI, with its ability to reduce migraine frequency and severity and improve cognitive symptoms, has the potential to play a significant role in promoting longevity and improving quality of life for individuals with migraines.
As we look to the future, it is essential to consider the impact of migraines and related cognitive symptoms on daily life and overall well-being. By developing effective treatments that address these symptoms, we can promote healthy aging and longevity, reducing the burden of migraines on individuals and society. The findings of this study highlight the importance of considering cognitive symptoms in the treatment of migraines and demonstrate the potential of VYEPTI to improve daily life and overall well-being for individuals with migraines.
About Menshly Life
Advancing human potential through science and AI. Follow on X
0 Comments